Stock Track | ADMA Biologics Plunges 24% Post-Market on Earnings Miss and Withdrawn Long-Term Guidance

Stock Track05-07

ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term guidance.

The specialty biologics maker reported Q1 revenue of $114.5 million, significantly missing the analyst consensus estimate of $141.8 million. Adjusted net income for the quarter was $40.7 million, also falling short of expectations. The company attributed the revenue pressure primarily to a 54% year-over-year decline in BIVIGAM sales, driven by increased competition and distributor ordering variability.

In a move that heightened investor concerns, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. While the company provided fiscal year 2026 revenue guidance of $530 million to $560 million, the removal of the longer-term outlook signaled uncertainty about future growth prospects amid heightened market competition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160683313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160683313","market":"hk","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Plunges 24% Post-Market on Earnings Miss and Withdrawn Long-Term Guidance","media":"Stock Track","content":"<p>ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term guidance.</p><p>The specialty biologics maker reported Q1 revenue of $114.5 million, significantly missing the analyst consensus estimate of $141.8 million. Adjusted net income for the quarter was $40.7 million, also falling short of expectations. The company attributed the revenue pressure primarily to a 54% year-over-year decline in BIVIGAM sales, driven by increased competition and distributor ordering variability.</p><p>In a move that heightened investor concerns, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. While the company provided fiscal year 2026 revenue guidance of $530 million to $560 million, the removal of the longer-term outlook signaled uncertainty about future growth prospects amid heightened market competition.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Plunges 24% Post-Market on Earnings Miss and Withdrawn Long-Term Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Plunges 24% Post-Market on Earnings Miss and Withdrawn Long-Term Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term guidance.</p><p>The specialty biologics maker reported Q1 revenue of $114.5 million, significantly missing the analyst consensus estimate of $141.8 million. Adjusted net income for the quarter was $40.7 million, also falling short of expectations. The company attributed the revenue pressure primarily to a 54% year-over-year decline in BIVIGAM sales, driven by increased competition and distributor ordering variability.</p><p>In a move that heightened investor concerns, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. While the company provided fiscal year 2026 revenue guidance of $530 million to $560 million, the removal of the longer-term outlook signaled uncertainty about future growth prospects amid heightened market competition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1160683313","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160683313","pubTimestamp":1778112296,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"个股追踪|ADMA Biologics盘后暴跌24%，因盈利未达预期且撤回长期指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term guidance.The specialty biologics maker reported Q1 revenue of $114.5 million, significantly missing the analyst consensus estimate of $141.8 million. Adjusted net income for the quarter was $40.7 million, also falling short of expectations. The company attributed the revenue pressure primarily to a 54% year-over-year decline in BIVIGAM sales, driven by increased competition and distributor ordering variability.In a move that heightened investor concerns, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. While the company provided fiscal year 2026 revenue guidance of $530 million to $560 million, the removal of the longer-term outlook signaled uncertainty about future growth prospects amid heightened market competition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160683313","isCrawlerRequest":true}